Imaging and biopsy of HIV-infected individuals undergoing analytic treatment interruption

Chuen‐Yen Lau, Matthew A. Adan, Jessica Earhart, Cassie Seamon, Thuy Nguyen, Ariana Savramis, Lindsey Adams, Mary-Elizabeth Zipparo, Erin Madeen, Kristi Huik, Zehava Grossman, Benjamin Chimukangara, Wahyu Nawang Wulan, Corina Millo, Avindra Nath, Bryan Smith, Ana M. Ortega‐Villa, Michael A. Proschan, Bradford J. Wood, Dima A. Hammoud, Frank MaldarelliFrontiers in Medicine 2022 · DOI

Abstract

Identifier: NCT05419024. This protocol outlines a clinical study designed to map the HIV reservoir using FDG-PET/CT imaging to identify metabolic "hot spots" in lymphoid tissue during Analytic Treatment Interruption (ATI).

Introduction: The Challenge of the HIV Reservoir

Antiretroviral Therapy (ART) has transformed HIV into a manageable chronic condition by suppressing viral loads to undetectable levels in the blood. However, ART is not a cure. The virus persists in latent "reservoirs," primarily within lymphoid tissues such as lymph nodes and the spleen. Upon cessation of ART, the virus typically rebounds from these sites.

A significant gap in current HIV research is the lack of spatial understanding regarding this rebound. While we know the virus returns, identifying the specific "factories" or anatomical locations where replication resumes in a living patient remains difficult. Traditional peripheral blood mononuclear cell (PBMC) analysis lacks spatial context. To advance "shock and kill" or "block and lock" strategies, researchers require non-invasive methods to visualize and target these active reservoirs.

Study Design and Methods

The proposed study (NCT05419024) is a single-site randomized trial involving 12 HIV-infected adults who have maintained viral suppression on ART for at least three years.

Figure 4: Flowchart illustrating the study protocol, including randomization into ATI and ART-continuation arms, imaging schedules, and biopsy timings.

Randomization and Intervention

Participants are randomized 1:1 into two groups:

  1. Analytic Treatment Interruption (ATI) Arm (n=6): Participants temporarily pause ART under rigorous clinical supervision.
  2. Control Arm (n=6): Participants continue their standard ART regimen.

Imaging and Precision Biopsy

The study utilizes $^{18}$F-fluorodeoxyglucose (FDG) PET/CT imaging. FDG, a glucose analog, identifies areas of high metabolic activity, which may correlate with active viral replication or localized immune activation.

Following imaging, interventional radiologists perform precision biopsies on both "hot" (high FDG uptake) and "cold" (low uptake) lymph nodes. This is achieved using advanced guidance systems, including electromagnetic tracking and ultrasound, to ensure accurate tissue sampling. Biopsies occur at three critical time points: baseline, approximately 10 days post-ART interruption (during the rebound phase), and after ART resumption once viral suppression is re-established.

Comprehensive Sample Collection and Analysis

The protocol mandates the collection of diverse biological samples to provide a multi-dimensional view of the viral reservoir and immune response.

Figure 5: Detailed table of samples to be collected (blood, leukocytes, CSF, tissue, etc.), collection methods, and planned molecular and cellular analyses.

Beyond lymphoid tissue, the study collects peripheral blood, leukocytes via leukapheresis, and optional samples such as cerebrospinal fluid (CSF) and semen/vaginal fluid. Analyses include HIV DNA/RNA quantification, genetic sequencing for viral evolution tracking, and detailed immune cell profiling.

Key Hypotheses and Anticipated Insights

The central hypothesis is that metabolic activity, as measured by FDG-PET, serves as a reliable proxy for the active HIV reservoir.

  • Correlation of SUV and Viral Load: Researchers anticipate a positive correlation between PET Standardized Uptake Values (SUV) and the concentration of HIV RNA in biopsy samples.
  • Spatial Heterogeneity: By comparing "hot" and "cold" nodes, the study aims to determine if PET imaging can distinguish between active replication sites and latent reservoirs.
  • Viral Dynamics: Phylogenetic analysis of rebound virus is expected to reveal the diversity of the initial rebound population before it potentially narrows to a dominant plasma clone.

Limitations and Future Directions

As a pilot study with 12 participants, the primary goal is proof-of-concept. A significant challenge is the non-specificity of FDG, which marks general inflammation as well as HIV-specific activity. Furthermore, ATI involves inherent risks, such as the development of drug resistance or acute retroviral syndrome.

If successful, this imaging-guided biopsy approach could revolutionize how we evaluate HIV cure interventions, providing a visual "map" to monitor whether new therapies effectively suppress the reservoir in its anatomical hiding places.

Summary updated

Abstract

Identifier: NCT05419024.
BibTeX
@inproceedings{lau2022imaging,
  author = {Chuen‐Yen Lau and Matthew A. Adan and Jessica Earhart and Cassie Seamon and Thuy Nguyen and Ariana Savramis and Lindsey Adams and Mary-Elizabeth Zipparo and Erin Madeen and Kristi Huik and Zehava Grossman and Benjamin Chimukangara and Wahyu Nawang Wulan and Corina Millo and Avindra Nath and Bryan Smith and Ana M. Ortega‐Villa and Michael A. Proschan and Bradford J. Wood and Dima A. Hammoud and Frank Maldarelli},
  title = {{Imaging and biopsy of HIV-infected individuals undergoing analytic treatment interruption}},
  booktitle = {Frontiers in Medicine},
  year = {2022},
  doi = {10.3389/fmed.2022.979756},
}
Figure